Characterization of an etoposide-resistant human small-cell lung cancer cell line Koichi MinatoFumihiko KanzawaNagahiro Saijo OriginalPaper Pages: 313 - 317
Enhancement of anthracycline and alkylator cytotoxicity by ethacrynic acid in primary cultures of human tissues Robert A. NagourneyJohn C. MessengerLarry M. Weisenthal OriginalPaper Pages: 318 - 322
Effect of ribonucleotide reductase inhibitors on the growth of human colon carcinoma HT-29 cells in culture Masahiko MatsumotoTarik TihanJoseph G. Cory OriginalPaper Pages: 323 - 329
Serum kinetics of the anti-cancer agent 4-hydroxyandrostenedione in the rat Jamal KhubiehG. Wynne AherneJagadish Chakraborty OriginalPaper Pages: 330 - 332
Mitomycin C cross-resistance induced by Adriamycin in human ovarian cancer cells in vitro Kimio MizunoYoshihito FuruhashiYutaka Tomoda OriginalPaper Pages: 333 - 339
Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells Monica LimontaAndrea BiondiMaurizio D’Incalci OriginalPaper Pages: 340 - 342
A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors Peter C. AdamsonSolomon ZimmDavid G. Poplack OriginalPaper Pages: 343 - 344
Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase Giuseppe NocentiniAnna BarziPalmarisa Franchetti OriginalPaper Pages: 345 - 351
Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer Takanobu YoshidaEiji ArakiNobuo Okazaki OriginalPaper Pages: 352 - 354
Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients J. P. SculierJ. J. BodyM. Paesmans OriginalPaper Pages: 355 - 358
Phase I toxicity and pharmacology study of trimethylcolchicinic acid in patients with advanced malignancies Eddie HuRichard KoFranco Muggia OriginalPaper Pages: 359 - 364
Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma Etienne ChatelutChristine ChevreauRoland Bugat OriginalPaper Pages: 365 - 368
Phase II study of carboplatin in untreated, inoperable non-small-cell lung cancer Ulrich GatzemeierMarlene HeckmayrLuigi Lenaz OriginalPaper Pages: 369 - 372
Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study Ryoichi HondaAkihisa FujitaAkira Suzuki OriginalPaper Pages: 373 - 376
Phase I trial of indicine-N-oxide in children with leukemia and solid tumors: a Pediatric Oncology Group study V. Michael WhiteheadMark L. BernsteinJeffrey Krischer OriginalPaper Pages: 377 - 379
Induction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposide Raymond LiangEdmond ChiuDavid Todd Short Communication Pages: 380 - 382
Statin expression in the untreated and SarCNU-exposed human glioma cell line, SK-MG-1 Hyman M. SchipperVioletta SkalskiEugenia Wang Short Communication Pages: 383 - 386
Identification of anthracyclines and related agents that retain preferential activity over Adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A Helen M. ColeyPeter R. TwentymanPaul Workman Erratum Pages: 387 - 388
